Johnson & Johnson is seeking buyers for its sterilization products division, as the health-care conglomerate continues to sell off non-core assets, Bloomberg reported citing people familiar with the matter.
J&J is working with an adviser to solicit bids for the unit, which could fetch as much as $2 billion, the report said. The asset is drawing interest from strategic buyers as well as private equity firms, the people said. Bids are due this week.
No final decision has been made and J&J may choose not to divest the division, the report said.
The advanced sterilization products unit, known as ASP, makes systems and solutions to clean medical tools. Its products, which are sold globally, include the Sterrad system for sterilizing instruments and Cidex OPA solution for disinfecting scopes.
Source: RTT News
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.